The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants
- PMID: 2036824
- DOI: 10.1378/chest.99.6.1415
The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants
Abstract
Objective: to determine the relation of serum theophylline concentrations (STC) to the occurrence of cardiac arrhythmias in a population of hospitalized patients.
Study design: A cross-sectional study of 100 patients receiving theophylline who had electrocardiograms at the time STC had been obtained. Categorization was based on STC without knowledge of clinical status: group 1 (25) had STC less than 2.5 mg/L; group 2 (25), STC greater than or equal to 2.5 less than 10 (6.2 +/- 0.4) mg/L; group 3 (25), STC greater than or equal to 10 less than or equal to 20 (15.8 +/- 0.4) mg/L; and group 4 (25), STC greater than 20 (27.8 +/- 1.1) mg/L.
Setting: A university-affiliated teaching hospital.
Results: Two-thirds of the patients were receiving theophylline in an oral form, with a similar distribution found in all groups. Groups were not different with respect to age, clinical diagnoses, electrocardiographic patterns, arterial pH or gases, serum calcium, or treatment with beta-agonists. Although fewer patients in group 1 were receiving steroids than those in the other groups, and serum potassium was lower in group 3 than in group 1 (4.0 +/- 0.6 vs 4.5 +/- 0.5 mEq/L, p less than 0.05), on multivariate analysis, serum potassium was not an independent predictor of arrhythmia, and treatment with steroids or digoxin was, at most, only weakly associated with the presence of arrhythmia. Heart rate was directly related to STC (r = 0.64, p less than 0.01), and STC was the strongest independent predictor of arrhythmia in this population. Although only 20 percent of patients in group 1 or 2 had arrhythmias, 48 percent of group 3 (p less than 0.05) and 56 percent of group 4 (p less than 0.05) had this finding. Moreover, the odds ratio of group 3 having an arrhythmia compared with group 1 was 3.7, 1.5 to 11.7, p less than 0.01. Multifocal atrial tachycardia was found in 8 percent of the patients in group 3 and 16 percent in group 4 but in none of the patients in groups 1 or 2. Two patients with multifocal atrial tachycardia died suddenly within 24 hours of having their STC measurement; none had concomitant ventricular ectopy.
Conclusion: Theophylline causes tachycardia and serious arrhythmias even at STC considered to be therapeutic. Multifocal atrial tachycardia, an arrhythmia associated with use of this drug, may herald sudden cardiac death.
Similar articles
-
Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study.Chest. 1990 Sep;98(3):672-8. doi: 10.1378/chest.98.3.672. Chest. 1990. PMID: 2394145
-
Multifocal atrial tachycardia: a toxic effect of theophylline.Lancet. 1985 Jan 5;1(8419):12-4. doi: 10.1016/s0140-6736(85)90964-x. Lancet. 1985. PMID: 2856947
-
Theophylline toxicity: clinical features of 116 consecutive cases.Am J Med. 1990 Jun;88(6):567-76. doi: 10.1016/0002-9343(90)90519-j. Am J Med. 1990. PMID: 2189301 Review.
-
Atrial arrhythmias exacerbated by theophylline. Response to verapamil and evidence for triggered activity in man.Chest. 1985 Dec;88(6):931-4. doi: 10.1378/chest.88.6.931. Chest. 1985. PMID: 4064786
-
[Evaluation of hyperkinetic cardiac arrhythmia in chronic obstructive bronchopneumopathy].Minerva Cardioangiol. 1997 Sep;45(9):429-33. Minerva Cardioangiol. 1997. PMID: 9446064 Review. Italian.
Cited by
-
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.Drugs. 2024 Oct;84(10):1251-1273. doi: 10.1007/s40265-024-02086-5. Epub 2024 Sep 26. Drugs. 2024. PMID: 39327397 Free PMC article. Review.
-
Theophylline. Current thoughts on the risks and benefits of its use in asthma.Drug Saf. 1993 Jan;8(1):12-8. doi: 10.2165/00002018-199308010-00003. Drug Saf. 1993. PMID: 8471184 Review.
-
Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?Drugs. 2001;61(3):391-418. doi: 10.2165/00003495-200161030-00007. Drugs. 2001. PMID: 11293649 Review.
-
Sleep-Breathing Disorders and Heart Failure.Sleep Breath. 2000;4(3):103-112. doi: 10.1007/s11325-000-0103-0. Sleep Breath. 2000. PMID: 11868127
-
Treatment options for Cheyne-Stokes respiration and heart failure.Curr Heart Fail Rep. 2011 Sep;8(3):155-8. doi: 10.1007/s11897-011-0058-4. Curr Heart Fail Rep. 2011. PMID: 21491193 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical